Protara Therapeutic

Forecast & Rating8 analysts currently cover Protara Therapeutic, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $26.57, about 559.3% upside from the current price of $4.03. Price targets span a fair range, indicating some disagreement among institutions. For you, this means most professionals who study Protara Therapeutic closely still see room for the stock to rise. Data as of Jun 30, 2026; for reference only and not investment advice.